Indolent T-Cell Non-Hodgkin Lymphoma — Trials

Indolent T-Cell Non-Hodgkin Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

134 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 33
Recruiting: 16
Ph III recruiting: 0
Growth YoY: —
Industry share: 15%
Top sponsor: City of Hope Medical Center
Termination share: 46.8%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (31)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06470451	Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL(FLASH2)	terminated	Phase 3	70	SoligenixINDUSTRY	1	Jul 13, 2026	clinicaltrials
NCT02811783	Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL	terminated	Phase 3	59	Elorac, Inc.INDUSTRY	1	Oct 28, 2022	clinicaltrials